奧泰生物(688606.SH):與振德健康簽訂關於新冠抗原檢測試劑盒戰略合作框架協議書
格隆匯4月12日丨奧泰生物(688606.SH)公佈,2022年4月12日,公司與振德醫療用品股份有限公司全資子公司浙江振德健康科技有限責任公司(“振德健康”)在紹興簽訂了《關於新冠抗原檢測試劑盒戰略合作框架協議書》。
根據國務院應對新型冠狀病毒肺炎疫情聯防聯控機制綜合組印發的《關於印發新冠病毒抗原檢測應用方案(試行)的通知》,決定在核酸檢測基礎上,增加抗原檢測作為補充,進一步提高“早發現”能力。為有效利用雙方優勢資源,更好的服務疫情防控,雙方簽署了此次《戰略框架協議》,協議約定採取雙方雙品牌運作模式在國內市場進行奧泰生物生產的“新型冠狀病毒(2019-nCoV)抗原檢測試劑盒(乳膠法)”產品的市場推廣和銷售,並授權振德健康在國內各渠道(藥店零售線、電商零售線和院線等渠道)進行銷售。
此次《戰略框架協議》僅為雙方合作框架性協議,是雙方實施具體業務合作的指導性文件,未明確具體合作規模或金額,由實際業務開展中屆時簽署的具體採購協議或合同中進一步明確。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.